DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults.

Author(s): Bohmer G, Gleiter CH, Hunnemeyer A, Lahu G, Bethke TD

Affiliation(s): Department of Clinical Pharmacology, University of Tubingen, Tubingen, Konstanz, Germany.

Publication date & source: 2011-07, Int J Clin Pharmacol Ther., 49(7):451-60.

Publication type: Randomized Controlled Trial

OBJECTIVE: To investigate whether a pharmacokinetic drug-drug interaction exists between theophylline (THEO), a CYP1A2 substrate with a narrow therapeutic index, and the concomitant substrate roflumilast (ROF), a novel selective PDE4 inhibitor partially metabolized by CYP1A2. MATERIALS AND METHODS: In an open-label, 2-period, crossover study, Treatment A (oral ROF 500 mug q.d. on Days 6 - 10 in addition to oral THEO 375 mg b.i.d. on Days 1 - 10) and treatment B (oral ROF 500 mug q.d. on Days 1 - 5) were administered consecutively in random order to each of 24 healthy adult subjects. Both periods were separated by a wash-out phase of at least 10 days. Plasma samples for pharmacokinetic evaluation (AUC, Cmax, t1/2, tmax) including percent peak-trough fluctuation (%PTF) of THEO were taken. Point estimates and the 90% confidence interval of the geometric mean ratios were calculated for AUC and Cmax and descriptive statistics for other pharmacokinetic parameters. RESULTS: Concomitant administration of ROF did not alter pharmacokinetics of THEO. With coadministered THEO, only steady-state total exposure to ROF (AUC) was increased by 28% whereas other pharmacokinetic parameters (t1/2, Cmax, tmax) of ROF and of the active metabolite roflumilast-N-oxide (R-NO), its main contributor to the pharmacodynamic effects, remained unchanged. CONCLUSIONS: Neither ROF nor its main metabolite had any impact on the metabolism of the concomitant CYP1A2 substrate THEO in humans. Though co-administration of THEO resulted in a minor increase (28%) in total ROF exposure, no safety or tolerability concerns and no altered total PDE4 inhibition of both ROF and R-NO, were observed.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017